The scale of the $8.5 billion deal signed between Innovent Biologics Inc. and Eli Lilly and Co. is eye-catching, but the structure is the real signal. By shifting phase II oncology development to China while reserving global rights ex-greater China, the partners are testing a model that could reshape how multinational drugmakers source innovation as well as how Chinese biotechs create value. Read More
Global investors in med tech are confident about exit opportunities in the year ahead. The strategics have already started making acquisitions, the IPO window – which reopened last year – is expected to remain active, and the investment firms have companies in their portfolios that are well-positioned for exit. With fundamentals in the sector still robust, 2026 is expected to reward companies that deliver clear clinical value. Read More
Breye Therapeutics ApS reported positive phase Ib data for its oral gap junction modifier drug danegaptide in diabetic retinopathy and is now raising a €50 million (US$59.6 million) series A round to move into the next phase of development. Read More
As its GLP-1 rival goes after compounders, Eli Lilly and Co. started the week with news beyond its diabetes and obesity franchise. The company, which disclosed a new agreement with Innovent Biologics Ltd., followed up a short time later with plans to acquire Orna Therapeutics Inc., marking its latest foray in the in vivo therapy space. Read More
Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering. Read More
Iambic Therapeutics Inc.’s multiyear technology and discovery pact with Takeda Pharmaceutical Co. Ltd. could help the San Diego-based firm advance its own pipeline in a big way. Read More
True to its word, Novo Nordisk A/S filed a patent infringement lawsuit in U.S. district court against Hims & Hers Health Inc. over compounded versions of Novo’s semaglutide products. Read More
While in 2025 med-tech financings averaged $3.3 billion per month, January 2026 saw the sector bring in $1.52 billion across 39 transactions. It was the lowest monthly total since November 2024’s $924.59 million. However, a number of months last year saw fluctuating values, ranging from $1.65 billion in July to $8.26 billion in December 2025, indicating uncertainty as to how industry financings will shake out this year. Read More
The neural and neuroimmune mechanisms behind myocardial infarction-triggered cardiac events, immune responses and activation of the nervous system remain largely unexplored. The heart and the brain talk to each other in what is known as cardioception. This communication between the two organs is orchestrated through neurons of the vagus nerve or the dorsal root ganglia, among others. Researchers from the University of California, San Diego have now shown that the dynamics of these interactions may play a crucial role in modulating inflammation, repair and cardiac functioning. Read More
Beginning Feb. 2, 2026, medical technology news and analysis will be integrated into BioWorld, where curated coverage will continue as part of BioWorld’s core reporting. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Aro, Bayer, Denali, Field Medical, Genesys Spine, Hoya Vision, Neovac, Pulse, Roivant, Spruce, Uniqure. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Cerenovus, Clearmind, Coeptis, Diagnoly, GE Healthcare, Guard, Iovance, Lakeshore, Nugen, Polyrizon. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Akeso, Everest, GSK, Kelun-Biotech, Kite, Neurophet, P+F Products and Features, Partner Therapeutics, Pfizer, Spinal Resources, Zimmer Biomet. Read More
